---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-040526"
form_type: "8-K"
ticker: "BFRG"
cik: "0001829247"
company_name: "BullFrog AI Holdings, Inc."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:27:56.750527+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bullfrog AI publishes Cell Reports data supporting BF-114 for liver diseases; adds Dr. Lopa Mishra to advisory board

## Summary
- Study led by Dr. Lopa Mishra published in Cell Reports provides mechanistic evidence for BF-114 target β2-spectrin (SPTBN1 siRNA) in obesity, MASLD, MASH, and HCC.
- Findings show reducing β2-spectrin can halt progression of MASLD and MASH and reduce liver damage in animal models.
- Dr. Lopa Mishra, a globally recognized liver disease expert, joined Bullfrog AI's Scientific Advisory Board to guide BF-114 development.
- Bullfrog AI will use its bfLEAP AI platform to analyze single-cell data from animal models and human patients for further mechanistic insights.
- BF-114 is an siRNA targeting SPTBN1, aimed at treating obesity-related liver diseases with high unmet need.

## SEC filing metadata
- accession: 0001493152-24-040526
- form_type: 8-K
- ticker: BFRG
- cik: 0001829247
- company_name: BullFrog AI Holdings, Inc.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829247/000149315224040526/0001493152-24-040526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829247/000149315224040526/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-040526
- JSON: https://secwatch.observer/filing/0001493152-24-040526.json
- Plain text: https://secwatch.observer/filing/0001493152-24-040526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.